# Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

> **NCT03444870** · PHASE3 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 1053 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Gantenerumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03444870
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-06
- **Primary completion:** 2022-12-28
- **Final completion:** 2023-02-17
- **Target enrollment:** 1053 (ACTUAL)
- **Why stopped:** Decision to terminate development of Gantenerumab for treatment of prodromal/mild/early-stage Alzheimer's disease following results of a pre-planned analysis of the safety and efficacy of Gant in Graduate I\&II (WN29922/WN39658).
- **Last updated:** 2024-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03444870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03444870, "Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03444870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*